ArticleTargeted oncology2026
HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the first episode of our podcast series, we introduce the emerging landscape of HER2-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer. We explain what makes HER2-mutant NSCLC unique, from its epidemiology and biology to the molecular mechanisms driving cancer growth. We discuss the evolution of precision medicine in NSCLC, the role of HER2 as a therapeutic target, and how advances in molecular profiling have enabled the development of targeted therapies. The episode also covers the latest treatment strategies, including antibody-drug conjugates and tyrosine kinase inhibitors, and reviews the challenges and opportunities that define this aggressive cancer subtype. This podcast aims to enhance understanding of HER2-mutant NSCLC and the evolving therapeutic landscape that is reshaping management strategies for this aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.